Q1 2025 Journey Medical Corp Earnings Call Transcript
Key Points
- Journey Medical Corp (DERM) successfully launched Amrosi, a new oral rosacea treatment, contributing $2 million to the first quarter 2025 net product sales.
- The company reported a gross margin increase to 64% in Q1 2025, up from 54% in the prior year, due to a favorable product sales mix and reduced product costs.
- Amrosi's market introduction has been well-received, with positive feedback from healthcare providers and strong initial prescription volumes.
- Approximately 30% of commercially insured lives now have access to Amrosi, up from 20% in the previous quarter, indicating progress in payer coverage.
- The inclusion of Amrosi in the National Rosacea Society's treatment algorithms and its publication in JAMA Dermatology are expected to drive further clinical adoption and market uptake.
- Net revenue for Q1 2025 was only slightly higher at $13.1 million compared to $13 million in Q1 2024, indicating limited overall revenue growth.
- Legacy products experienced a decline, with a noted decrease in prescriptions for Accutane due to increased competition and aggressive pricing by new market entrants.
- SG&A expenses increased by $2.1 million to $10.6 million in Q1 2025, reflecting higher investments in commercial infrastructure for the Amrosi launch.
- The company reported a net loss to common shareholders of $4.1 million for Q1 2025, although this was an improvement from the $10.4 million loss in Q1 2024.
- There is uncertainty regarding the sustainability of initial Amrosi sales, as the Q1 revenue included significant stocking, and future revenues will need to reflect actual demand.
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to Journey Medical's first quarter 2025 Financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0.
Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of this call will be available approximately 1 hour after the end of the call for approximately 30 days.
I would now like to turn the call over to Jaclyn Jaffe, the company's senior director of corporate operations. Please go ahead, Jaclyn.
Good afternoon and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Moraly, co-founder, President and Chief Executive Officer, and Joseph Banash, Chief Financial Officer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
